Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

Small cell lung cancer (SCLC) is a highly aggressive malignancy with few therapeutic advances in the treatment in recent decades. Based on a recent study that identified the spliceosome as a therapeutic vulnerability in MYC-driven breast cancers, we evaluated the efficacy of a spliceosome inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Suda, Kenichi, Rozeboom, Leslie, Yu, Hui, Ellison, Kim, Rivard, Christopher J., Mitsudomi, Tetsuya, Hirsch, Fred R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305228/
https://www.ncbi.nlm.nih.gov/pubmed/28192473
http://dx.doi.org/10.1371/journal.pone.0172209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305228/
https://www.ncbi.nlm.nih.gov/pubmed/28192473
http://dx.doi.org/10.1371/journal.pone.0172209

Ejemplares similares